J. Majcher‐Peszynska

The extent of induction of CYP3A by St. John’s wort varies among products and is linked to hyperforin dose

Silke Mueller, J. Majcher‐Peszynska, Bernhard Uehleke et al. · European Journal of Clinical Pharmacology · 2005 · 117 citations

Molecular Pharmacology, St. John ’, Medicine +3

Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration

Olaf Burkhardt, Vipul Kumar, D. Katterwe et al. · Journal of Antimicrobial Chemotherapy · 2006 · 117 citations · Full text

Pharmacokinetics of Piperacillin-Tazobactam in Anuric Intensive Care Patients during Continuous Venovenous Hemodialysis

Silke Mueller, J. Majcher‐Peszynska, Heiko Hickstein et al. · Antimicrobial Agents and Chemotherapy · 2002 · 80 citations · Full text

Dialysis Therapy, Pharmacotherapy, Pharmacokinetics +19

No clinically relevant CYP3A induction after St. John’s wort with low hyperforin content in healthy volunteers

Silke Mueller, J. Majcher‐Peszynska, Ralf G. Mundkowski et al. · European Journal of Clinical Pharmacology · 2008 · 61 citations · Full text

Healthy Volunteers, Pathology, Low Hyperforin Content +2

Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections

J. Majcher‐Peszynska, G. Haase, Marko Saß et al. · European Journal of Clinical Pharmacology · 2008 · 47 citations

Diabetic Foot Infections, Diabetes, Pharmacology +6